PLGA Nanoparticle-mediated Delivery of Tumor Antigenic Peptides Elicits Effective Immune Responses

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2012 May 24

PMID 22619507

Citations 50

Authors

Wenxue Ma

Mingshui Chen

Sharmeela Kaushal

Michele McElroy

Yu Zhang

Cengiz Ozkan

Michael Bouvet

Carol Kruse

Douglas Grotjahn

Thomas Ichim

Boris Minev

Affiliations

Soon will be listed here.

Abstract

The peptide vaccine clinical trials encountered limited success because of difficulties associated with stability and delivery, resulting in inefficient antigen presentation and low response rates in patients with cancer. The purpose of this study was to develop a novel delivery approach for tumor antigenic peptides in order to elicit enhanced immune responses using poly(DL-lactide-co-glycolide) nanoparticles (PLGA-NPs) encapsulating tumor antigenic peptides. PLGA-NPs were made using the double emulsion-solvent evaporation method. Artificial antigen-presenting cells were generated by human dendritic cells (DCs) loaded with PLGA-NPs encapsulating tumor antigenic peptide(s). The efficiency of the antigen presentation was measured by interferon-γ ELISpot assay (Vector Laboratories, Burlingame, CA). Antigen-specific cytotoxic T lymphocytes (CTLs) were generated and evaluated by CytoTox 96(®) Non-Radioactive Cytotoxicity Assay (Promega, Fitchburg, WI). The efficiency of the peptide delivery was compared between the methods of emulsification in incomplete Freund's adjuvant and encapsulation in PLGA-NPs. Our results showed that most of the PLGA-NPs were from 150 nm to 500 nm in diameter, and were negatively charged at pH 7.4 with a mean zeta potential of -15.53 ± 0.71 mV; the PLGA-NPs could be colocalized in human DCs in 30 minutes of incubation. Human DCs loaded with PLGA-NPs encapsulating peptide induced significantly stronger CTL cytotoxicity than those pulsed with free peptide, while human DCs loaded with PLGA-NPs encapsulating a three-peptide cocktail induced a significantly greater CTL response than those encapsulating a two-peptide cocktail. Most importantly, the peptide dose encapsulated in PLGA-NPs was 63 times less than that emulsified in incomplete Freund's adjuvant, but it induced a more powerful CTL response in vivo. These results demonstrate that the delivery of peptides encapsulated in PLGA-NPs is a promising approach to induce effective antitumor CTL responses in vivo.

Citing Articles

Recent Advances in Peptide-Loaded PLGA Nanocarriers for Drug Delivery and Regenerative Medicine.

Omidian H, Wilson R, Castejon A Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861188 PMC: 11768227. DOI: 10.3390/ph18010127.

Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance.

Yao L, Wang Q, Ma W Cancers (Basel). 2023; 15(24).

PMID: 38136402 PMC: 10742031. DOI: 10.3390/cancers15245857.

Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects.

Nordin M, Azemi A, Nordin A, Nabgan W, Ng P, Yusoff K Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513835 PMC: 10386531. DOI: 10.3390/ph16070923.

Immunoinformatics Approach to Design a Multi-Epitope Nanovaccine against Parasite: Elicitation of Cellular Immune Responses.

Margaroni M, Agallou M, Tsanaktsidou E, Kammona O, Kiparissides C, Karagouni E Vaccines (Basel). 2023; 11(2).

PMID: 36851182 PMC: 9960668. DOI: 10.3390/vaccines11020304.

PLGA Particles in Immunotherapy.

Horvath D, Basler M Pharmaceutics. 2023; 15(2).

PMID: 36839937 PMC: 9965784. DOI: 10.3390/pharmaceutics15020615.

References

Rew S, Peggs K, Sanjuan I, Pizzey A, Koishihara Y, Kawai S . Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24. Clin Cancer Res. 2005; 11(9):3377-84. DOI: 10.1158/1078-0432.CCR-04-0650. View

de Vries I, Lesterhuis W, Barentsz J, Verdijk P, van Krieken J, Boerman O . Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005; 23(11):1407-13. DOI: 10.1038/nbt1154. View

Tsai Y, Chien C, Lin L, Tsai T . Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm. 2011; 416(1):331-8. DOI: 10.1016/j.ijpharm.2011.06.030. View

Yang D, Holt G, Velders M, Kwon E, Kast W . Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate.... Cancer Res. 2001; 61(15):5857-60. View

Rosenberg S, Kawakami Y, Robbins P, Wang R . Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res. 1996; 70:145-77. DOI: 10.1016/s0065-230x(08)60874-x. View

Mandelboim O, Vadai E, Fridkin M, Feldman M, Berke G, Eisenbach L . Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med. 1995; 1(11):1179-83. DOI: 10.1038/nm1195-1179. View

Ma W, Yu H, Wang Q, Jin H, Solheim J, Labhasetwar V . A novel approach for cancer immunotherapy: tumor cells with anchored superantigen SEA generate effective antitumor immunity. J Clin Immunol. 2004; 24(3):294-301. DOI: 10.1023/B:JOCI.0000025451.41948.94. View

Prabha S, Zhou W, Panyam J, Labhasetwar V . Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm. 2002; 244(1-2):105-15. DOI: 10.1016/s0378-5173(02)00315-0. View

Lehner P, Cresswell P . Processing and delivery of peptides presented by MHC class I molecules. Curr Opin Immunol. 1996; 8(1):59-67. DOI: 10.1016/s0952-7915(96)80106-3. View

10.

Ito F, Fujimori H, Makino K . Factors affecting the loading efficiency of water-soluble drugs in PLGA microspheres. Colloids Surf B Biointerfaces. 2007; 61(1):25-9. DOI: 10.1016/j.colsurfb.2007.06.029. View

11.

Yadav K, Chuttani K, Mishra A, Sawant K . Effect of Size on the Biodistribution and Blood Clearance of Etoposide-Loaded PLGA Nanoparticles. PDA J Pharm Sci Technol. 2011; 65(2):131-9. View

12.

Acharya S, Sahoo S . PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2010; 63(3):170-83. DOI: 10.1016/j.addr.2010.10.008. View

13.

Newman K, Samuel J, Kwon G . Ovalbumin peptide encapsulated in poly(d,l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J Control Release. 1998; 54(1):49-59. DOI: 10.1016/s0168-3659(97)00142-9. View

14.

Steinman R . Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system. Nat Med. 2007; 13(10):1155-9. DOI: 10.1038/nm1643. View

15.

Elamanchili P, Diwan M, Cao M, Samuel J . Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine. 2004; 22(19):2406-12. DOI: 10.1016/j.vaccine.2003.12.032. View

16.

Rosenberg S, Yang J, Restifo N . Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004; 10(9):909-15. PMC: 1435696. DOI: 10.1038/nm1100. View

17.

Alexis F, Pridgen E, Molnar L, Farokhzad O . Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5(4):505-15. PMC: 2663893. DOI: 10.1021/mp800051m. View

18.

Sahoo S, Ma W, Labhasetwar V . Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer. 2004; 112(2):335-40. DOI: 10.1002/ijc.20405. View

19.

Garcia-Hernandez M, Gray A, Hubby B, Kast W . In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res. 2007; 67(3):1344-51. DOI: 10.1158/0008-5472.CAN-06-2996. View

20.

Lutsiak M, Kwon G, Samuel J . Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol. 2006; 58(6):739-47. DOI: 10.1211/jpp.58.6.0004. View